Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?

JOP. 2013 Jan 10;14(1):102-4. doi: 10.6092/1590-8577/1354.
No abstract available

Publication types

  • News

MeSH terms

  • Administration, Oral
  • Angiogenesis Inhibitors / economics
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Cost-Benefit Analysis
  • Everolimus
  • Humans
  • Indoles / economics
  • Indoles / therapeutic use*
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / pathology
  • Outcome Assessment, Health Care / economics
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Pyrroles / economics
  • Pyrroles / therapeutic use*
  • Sirolimus / analogs & derivatives*
  • Sirolimus / economics
  • Sirolimus / therapeutic use
  • Sunitinib

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Everolimus
  • Sunitinib
  • Sirolimus